16 February 2012
Ellex To Spotlight Evolving Role Of SLT For Glaucoma
Ellex Medical Lasers Limited, a manufacturer and distributor of ophthalmic technology for use in the fight against blindness, today announced that it will bring together some of the world’s leading SLT practitioners at the Company’s SLT Physician Forum during the World Ophthalmology Congress (WOC) in Abu Dhabi, 16 – 20 February 2012.
The forum will center on the evolving role of SLT (selective laser trabeculoplasty) for glaucoma treatment, providing participants with the opportunity to share their clinical experience and insight into how to improve the results of SLT in daily clinical practice.
Non-invasive and non-thermal, SLT is an advanced laser therapy which stimulates a natural healing response in the body to manage the elevated intraocular pressure associated with glaucoma. Highly effective, SLT is used as a primary treatment option for the early stages of glaucoma, and can be used in combination with drug therapy or as an alternative therapy when drugs fail. It is a flexible treatment option given that it can be repeated, if necessary, depending on the individual patient’s response.
Since the introduction of its SLT technology in 2005, Ellex has been at the forefront of global efforts to raise awareness of the many benefits of SLT – both for physicians and their patients, and for the wider healthcare system.
Forum moderator and leading proponent of SLT, Prof. Philippe Denis, MD, PhD, of the University Hospitals of Lyon, France, and President of the French Ophthalmology Society, has successfully performed hundreds of SLT treatments and believes that it is a significant addition to the treatment armamentarium for primary open-angle glaucoma (POAG).
“Along with medications and surgery, SLT has become an important treatment option for glaucoma patients in France. More than 100 clinical centers are now equipped with SLT technology,” commented Prof. Denis.
In addition to its many patient benefits, Prof. Denis believes that it is the treatment’s proven clinical efficacy, in which patients can expect to experience a drop in intraocular pressure from 20 to 30 percent (on average) following treatment, that has seen SLT become so widely adopted in the treatment of glaucoma.
“SLT has an excellent safety profile. Because the energy and exposure time of SLT treatment are much lower than ALT and create no harm to the trabecular meshwork (TM), repeat treatments show excellent results without compromising the outcome of future surgery, if it is required.”
The Ellex SLT Physician Forum will be held on Saturday, 18 February 2012. A summary of the forum discussion and video interviews with each of the participants will shortly be available for download via the dedicated Ellex SLT website, www.slt-ellex.com.
Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the design and manufacture of ophthalmic laser and ultrasound systems used by ophthalmologists to diagnose and treat eye disease. With more than 15,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries.
ABOUT SLT FROM ELLEX
- The Tango™ SLT/YAG combination laser system allows you to instantly switch between SLT and photodisruptor modes at the touch of a button – making procedures as efficient as possible.
- The Solo™ SLT laser enables you to provide your glaucoma patients with quick and highly accurate SLT treatment, maximizing treatment options and ensuring effective patient results.
For more information about SLT from Ellex, visit www.slt-ellex.com.